Business Context and Reporting Period
This Form 8-K Current Report was filed by Oculus Innovative Sciences, Inc. (not Sonoma Pharmaceuticals, Inc., as noted in the metadata) on March 27, 2008. The filing discloses the entry into a material definitive agreement regarding a private placement offering of equity securities.
Key Financial Metrics and Transaction Details
The filing details a capital raise transaction rather than standard operating financial metrics. Key terms include:
- Securities Issued: Up to 2,652,673 shares of Common Stock and warrants to purchase up to 1,326,337 shares.
- Offering Price: $5.25 per Unit (one share of Common Stock plus one-half of one Warrant).
- Warrant Terms: Initial exercise price of $6.85 per share; exercisable starting September 28, 2008, through September 28, 2013.
- Placement Agent: Rodman & Renshaw, LLC.
- Agent Compensation: 7% of the gross purchase price of the Units plus 130,000 warrants exercisable at $6.30 per share.
Note: The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material change is the execution of a Placement Agency Agreement and Securities Purchase Agreement to raise capital. This transaction is being conducted pursuant to a shelf registration statement on Form S-3 (Registration No. 333-149223) declared effective on February 26, 2008.
Outlook, Risks, and Management Commentary
Management commentary is limited to the announcement of the pricing of the offer and sale of Units, referenced in a press release issued on March 28, 2008 (Exhibit 99.1). The filing does not explicitly detail future guidance, specific risks, or contingencies beyond the standard terms of the warrant exercise periods and the best-efforts basis of the placement agent.
Investor Verification Checklist
- Verify the final number of Units sold and total gross proceeds raised, as the filing states "up to" 2,652,673 shares.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for investor-specific covenants or restrictions.
- Confirm the impact of the 7% placement fee and agent warrants on the net proceeds available to the company.
- Check the press release (Exhibit 99.1) for the intended use of proceeds from this offering.
- Monitor the dilution impact on existing shareholders given the warrant exercise price ($6.85) relative to the offering price ($5.25).